Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CNOT7 | Q9UIV1 | 5/20 | 0.38 |
| ▸ | PARN | O95453 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7318570 | 0.86 | GDA (0.55) | GDAADORA2BKDM4ECNOT7PARN | |
| SCHEMBL18175050 | 0.86 | GDA (0.51) | GDACNOT7PARN | |
| SCHEMBL9161807 | 0.82 | GDA (0.57) | GDAALDH1A1CNOT7PARN | |
| SCHEMBL5512566 | 0.79 | GDA (0.57) | GDALMNAALDH1A1CNOT7PARN | |
| SCHEMBL9194843 | 0.79 | GDA (0.62) | GDAADORA2BLMNAALDH1A1 | |
| SCHEMBL9197448 | 0.79 | GDA (0.57) | GDALMNAALDH1A1CNOT7PARN | |
| SCHEMBL843472 | 0.78 | GDA (0.53) | GDAADORA2BALDH1A1CNOT7PARN | |
| SCHEMBL10408059 | 0.77 | GDA (0.55) | GDACSNK2A2CSNK2A1ALDH1A1CNOT7 | |
| SCHEMBL1460591 | 0.76 | GDA (0.63) | GDAADORA2BALDH1A1CNOT7 | |
| SCHEMBL18175233 | 0.76 | GDA (0.50) | GDALMNACNOT7PARN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260072035-A1 | ENHANCED SPECIFICITY MASS TAG DNA ADDUCTOMICS | UNIV NORTHEASTERN (US) | 2026-03-12 | — | — | US | disclosed |
| US-12559495-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-02-24 | — | — | US | disclosed |
| EP-4511513-A1 | ENHANCED SPECIFICITY MASS TAG DNA ADDUCTOMICS | Northeastern University (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023239572-A1 | ENHANCED SPECIFICITY MASS TAG DNA ADDUCTOMICS | NORTHEASTERN UNIVERSITY (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-01-17 | — | — | US | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007073505-A2 | TRPA1 INHIBITORS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555037-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, WNT3 | GDA 340/4885CSNK2A2 1009/4885CSNK2A1 1056/4885 |
| US-20260072035-A1 | ENHANCED SPECIFICITY MASS TAG DNA ADDUCTOMICS | DNMT3A, APEX1, CHAMP1 | GDA 1854/4885CSNK2A2 2960/4885CSNK2A1 2888/4885 |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | GDA 1971/4885CSNK2A2 1037/4885CSNK2A1 1183/4885 |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | GDA 3705/4885CSNK2A2 2282/4885CSNK2A1 2279/4885 |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | GDA 340/4885CSNK2A2 1009/4885CSNK2A1 1056/4885 |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | GDA 340/4885CSNK2A2 1009/4885CSNK2A1 1056/4885 |
| US-12559495-B2 | Purine diones as Wnt pathway modulators | WNT1, CTNND1, WNT3A | GDA 1359/4885CSNK2A2 161/4885CSNK2A1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.